143 related articles for article (PubMed ID: 35987499)
1. Prevention and treatment of COVID-19 infection by earthing.
Mousa HA
Biomed J; 2023 Feb; 46(1):60-69. PubMed ID: 35987499
[TBL] [Abstract][Full Text] [Related]
2. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
6. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
8. [Clinical Characteristics of Mild-Moderate COVID-19 Patients and Risk Factors for the Development of Pneumonia].
Özdemir YE; Balkan İİ; Bayramlar OF; Alkan S; Murt A; Karaali R; Mete B; Kuşkucu MA; Aygün G; Keskindemirci Y; Öngören Ş; Kutlubay Z; Çetinkale O; Saltoğlu N; Tabak F
Mikrobiyol Bul; 2021 Jul; 55(3):342-356. PubMed ID: 34416801
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
10. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
11. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Struyf T; Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Leeflang MM; Spijker R; Hooft L; Emperador D; Domen J; Tans A; Janssens S; Wickramasinghe D; Lannoy V; Horn SRA; Van den Bruel A;
Cochrane Database Syst Rev; 2022 May; 5(5):CD013665. PubMed ID: 35593186
[TBL] [Abstract][Full Text] [Related]
12. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study.
Borch L; Holm M; Knudsen M; Ellermann-Eriksen S; Hagstroem S
Eur J Pediatr; 2022 Apr; 181(4):1597-1607. PubMed ID: 35000003
[TBL] [Abstract][Full Text] [Related]
13. Impact of isolation on the biopsychosocial functioning of older people with COVID-19.
Wróblewska IM; Chmielewski JP; Wojciechowska M; Chmielowiec B; Nowak-Starz G; Szarpak L; Florek-Łuszczki M
Ann Agric Environ Med; 2022 Dec; 29(4):560-567. PubMed ID: 36583324
[TBL] [Abstract][Full Text] [Related]
14. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
15. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
[TBL] [Abstract][Full Text] [Related]
16. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
17. Persisting Smell and Taste Disorders in Patients Who Recovered from SARS-CoV-2 Virus Infection-Data from the Polish PoLoCOV-CVD Study.
Chudzik M; Babicki M; Mastalerz-Migas A; Kapusta J
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016385
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study.
Makaronidis J; Mok J; Balogun N; Magee CG; Omar RZ; Carnemolla A; Batterham RL
PLoS Med; 2020 Oct; 17(10):e1003358. PubMed ID: 33001967
[TBL] [Abstract][Full Text] [Related]
19. Natural Language Processing for Improved Characterization of COVID-19 Symptoms: Observational Study of 350,000 Patients in a Large Integrated Health Care System.
Malden DE; Tartof SY; Ackerson BK; Hong V; Skarbinski J; Yau V; Qian L; Fischer H; Shaw SF; Caparosa S; Xie F
JMIR Public Health Surveill; 2022 Dec; 8(12):e41529. PubMed ID: 36446133
[TBL] [Abstract][Full Text] [Related]
20. Integrative and lifestyle medicine strategies should include Earthing (grounding): Review of research evidence and clinical observations.
Menigoz W; Latz TT; Ely RA; Kamei C; Melvin G; Sinatra D
Explore (NY); 2020; 16(3):152-160. PubMed ID: 31831261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
